Want to join the conversation?
Mike Weinstein of JPMorgan asks about 670G timing. $MDT Diabetes Group President Hooman Hakami replied that the PMA is with the FDA and it's hard to predict when they are going to approve it. He added that the company is working actively with the FDA on the 670G approval.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.